CYCLEGUARD 500- melengestrol acetate liquid 
Huvepharma, Inc

----------

CycleGuard® 500

(melengestrol acetate Type A liquid medicated article)

Heifers Fed in Confinement for Slaughter:
For Increased Rate of Weight Gain, Improved Feed Efficiency and Suppression of Estrus (Heat).

Heifers Intended for Breeding: For Suppression of Estrus (Heat).

Each Pound Contains:
   Active Drug Ingredient:
      Melengestrol Acetate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 500 mg
      (as melengestrol acetate and its propylene glycol ketal)
 Inactive Ingredient:
      Propylene Glycol, U.S.P. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99.89%

PRECAUTIONS: For manufacturing, processing, or repacking. To be mixed with feed prior to animal use.
Use only as directed. Excessive contact with skin should be avoided. Destroy empty container. Do not reuse.

Store at 4° - 25°C (39° - 77°F).
Excursions permitted up to 40°C (104°F).
Approved by FDA under ANADA #200-399
Net Weight 40 Pounds (18 kg)
(4.627gal [17.5 L])

HUVEPHARMA®

KCP-S00037
Version 02 Rev. 02-2022

DIRECTIONS FOR USE:
Heifers Fed in Confinement for Slaughter:
CycleGuard 500 (melengestrol acetate Type A liquid medicated article) should be thoroughly
mixed in liquid Type C medicated feed which must be fed at 0.5 to 2.0 pounds per head daily
to provide 0.25 to 0.5 mg of melengestrol acetate per head per day. Average daily intakes
approximating the middle of this range provide the most optimal and economical improvements
in rate of gain and feed utilization. Constant daily intakes of 0.35 to 0.50 mg per head per
day give a high degree of estrus suppression. Levels of 0.25 to 0.35 mg provide a lower but
still effective degree of estrus suppression.
Heifers Intended for Breeding:
CycleGuard 500 should be thoroughly mixed in the supplement to provide 0.5 mg of melengestrol
acetate per head per day.

WARNINGS: Not for human use. Restricted Drug (California)—Use Only As Directed
PRECAUTIONS: Not effective in steers and spayed heifers.

Heifers Fed in Confinement for Slaughter:
Withdrawal periods of three to five days or more should be avoided to prevent the
possibility that the heifers may come into estrus (heat) at loading time.
Heifers Intended for Breeding:
Do not exceed 24 days of feeding of melengestrol acetate to heifers intended for
breeding. A reduced conception rate can be expected if heifers are bred at estruses
observed within 1 to 12 days after withdrawal of melengestrol acetate, whereas heifers
bred at subsequent observed estruses are expected to have normal conception rates.

MIXING DIRECTIONS:
Liquid Type B and C medicated feeds containing melengestrol acetate must have
a pH of 4.0 to 8.0 and their labels must bear appropriate mixing directions.
Mixing directions for liquid Type B or C feeds stored in recirculation tank
systems are: "Recirculate immediately prior to use for no less than 10 minutes,
moving not less than 1 percent of the tank contents per minute from the bottom
of the tank to the top. Recirculate daily, as directed in this paragraph even
when the Type B (or C) feed is not used." Mixing directions for liquid Type B
and C feeds stored in mechanical, air or other agitation-type tank systems are:
"Agitate immediately prior to use for not less than 10 minutes, creating a
turbulence at the bottom of the tank that is visible at the top. Agitate daily,
as directed in this paragraph, even when the Type B (or C) feed is not used."
Intermediate medicated feeds should not be made from CycleGuard 500 except as
a part of a continuous mixing operation to make a complete liquid Type B or
Type C medicated feed.
Thoroughly mix 0.5 to 4 pounds of CycleGuard 500 per ton of a non-medicated
feed to prepare a Type C medicated feed containing 0.25 to 2.0 grams of
melengestrol acetate per ton. The following Table may be used as a guide
in determining the amount of CycleGuard 500 to be added to prepare a ton
of Type C medicated feed.

Dosing Table

Type B medicated feed containing 4 to 10 grams melengestrol acetate per ton may
be manufactured by thoroughly mixing 8 to 20 lbs of CycleGuard® 500 (melengestrol
acetate Type A liquid medicated article) with 1992 to 1980 lbs of non-medicated
feed. Labeling for such Type B feed shall contain directions for manufacturing
Type C medicated feeds containing 0.25 to 2.0 grams melengestrol acetate per ton
(0.125 to 1.0 mg/lb). The Type C medicated feed, containing melengestrol acetate,
must be top dressed on grain or roughage or mixed with a complete ration at the
rate of 0.5 to 2.0 pounds per head per day. Good manufacturing practice regulations
must be adhered to in manufacturing feeds containing CycleGuard 500.

To report suspected adverse drug events, for technical assistance or to obtain a copy
of the Safety Data Sheet (SDS), contact Huvepharma, Inc. at 1-877-994-4883 or
www.huvepharma.us. For additional information about adverse drug experience reporting
for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae.

Approved by FDA under ANADA #200-399

Manufactured For: Huvepharma, Inc
525 Westpark Dr. Suite 230
Peachtree City, GA 30269
1-877-994-4883

HUVEPHARMA®

CycleGuard 500 label page 1

CycleGuard 500 label page 2

CycleGuard 500 label page 3

CYCLEGUARD  500
melengestrol acetate liquid
Product Information
Product TypeOTC TYPE A MEDICATED ARTICLE ANIMAL DRUGItem Code (Source)NDC:23243-0068
Route of AdministrationORAL
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
MELENGESTROL ACETATE (UNII: 4W5HDS3936) (MELENGESTROL - UNII:BX98J4T6JU) MELENGESTROL ACETATE500 mg  in .45 kg
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:23243-0068-118 kg in 1 BOTTLE
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
ANADAANADA20039902/21/2021
Labeler - Huvepharma, Inc (619153559)

Revised: 5/2022
Document Id: ca1e0f6b-0e3a-41d0-be5b-f7abec4093ea
Set id: 3f843d3a-7250-4d3b-bd15-e8e32c9ddaae
Version: 2
Effective Time: 20220512
 
Huvepharma, Inc